Dipraglurant has been used in trials studying the treatment of Parkinson's Disease. It is a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM).
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.